Hematology Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hodgkin Disease Therapy
Study data from University of Milan, European Institute of Oncology update understanding of Hodgkin disease therapy
April 16th, 2007
New research, "Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors," is the subject of a report. According to recent research from Milan, Italy, "Better therapeutic approaches for patients with Hodgkin's disease (HD) and non-Hodgkin's lymphomas (NHL) resulted in high cure rates, at cost of serious late side effects. Second primary tumours are a major concern for long-term survivors, and breast cancer (BC) is the most common solid tumor among women treated for HD.: Fifty-three women treated for primary BC with previous history of malignant lymphoma were identified in our institution, 35 with HD (66%), 18 (34%) with NHL." "A comparison group was...
Source: Hematology Week (2007-04-16)
|
